Literature DB >> 7624149

Frequent deletion of chromosome 19 and a rare rearrangement of 19p13.3 involving the insulin receptor gene in human ovarian cancer.

K Amfo1, B Neyns, E Teugels, W Lissens, C Bourgain, P De Sutter, B Vandamme, E Vamos, J De Grève.   

Abstract

Human ovarian cancer cells usually have multiple specific chromosomal deletions which can be detected by cytogenetic analysis or molecular techniques. Tumour suppressor genes might be located in these deleted chromosomal segments. The importance of these different loci is usually estimated from the frequency with which they are deleted. Here we report a 59% loss of heterozygosity for chromosome 19 in the DNA of human invasive epithelial ovarian cancer from a series of 37 patients. In all cases informative on both chromosomal arms a subchromosomal loss is observed. Analysis of the same tumours for chromosome 17p and 11p loss suggests that loss of chromosome 19p/q is less important than 17p loss, but more important than 11p loss. The deletion of chromosome 19q seems to be associated with distant, hematogeneous metastasis (stage IV). In two patients with high grade tumours, the deletion involves a rearrangement of the insulin receptor locus (19p13.3). This suggests that some of the previously described frequent cytogenetic 19p+ markers and 19p13.3 breaks observed in high grade ovarian cancers, might actually occur in the insulin receptor gene.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7624149

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

1.  1,25-Dihydroxyvitamin D3 suppresses telomerase expression and human cancer growth through microRNA-498.

Authors:  Ravi Kasiappan; Zheng Shen; Anfernee K-W Tse; Umesh Jinwal; Jinfu Tang; Panida Lungchukiet; Yuefeng Sun; Patricia Kruk; Santo V Nicosia; Xiaohong Zhang; Wenlong Bai
Journal:  J Biol Chem       Date:  2012-10-10       Impact factor: 5.157

2.  RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells.

Authors:  Xiaosong Yang; You Pan; Zhaojun Qiu; Zhanwen Du; Yao Zhang; Pengyan Fa; Shashank Gorityala; Shanhuai Ma; Shunqiang Li; Ceshi Chen; Hongbing Wang; Yan Xu; Chunhong Yan; Keri Ruth; Zhefu Ma; Junran Zhang
Journal:  Clin Cancer Res       Date:  2018-01-11       Impact factor: 12.531

3.  Allelic imbalance regions on chromosomes 8p, 17p and 19p related to metastasis of hepatocellular carcinoma: comparison between matched primary and metastatic lesions in 22 patients by genome-wide microsatellite analysis.

Authors:  Lian-Hai Zhang; Lun-Xiu Qin; Zeng-Chen Ma; Sheng-Long Ye; Yin-Kun Liu; Qing-Hai Ye; Xin Wu; Wei Huang; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2003-05-07       Impact factor: 4.553

4.  In vivo Engineering of Chromosome 19 q-arm by Employing the CRISPR/AsCpf1 and ddAsCpf1 Systems in Human Malignant Gliomas (Hypothesis).

Authors:  Atefe Abak; Hamed Shoorei; Mohammad Taheri; Soudeh Ghafouri-Fard
Journal:  J Mol Neurosci       Date:  2021-05-15       Impact factor: 3.444

5.  Reduced expression of intercellular adhesion molecule-1 in ovarian adenocarcinomas.

Authors:  J M Arnold; M Cummings; D Purdie; G Chenevix-Trench
Journal:  Br J Cancer       Date:  2001-11-02       Impact factor: 7.640

6.  Allele loss and mutation screen at the Peutz-Jeghers (LKB1) locus (19p13.3) in sporadic ovarian tumours.

Authors:  Z J Wang; M Churchman; I G Campbell; W H Xu; Z Y Yan; W G McCluggage; W D Foulkes; I P Tomlinson
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

7.  Changes in IL-16 Expression in the Ovary during Aging and Its Potential Consequences to Ovarian Pathology.

Authors:  Jessica Ramirez; Pincas Bitterman; Sanjib Basu; Animesh Barua
Journal:  J Immunol Res       Date:  2022-04-26       Impact factor: 4.493

8.  RNF126 promotes homologous recombination via regulation of E2F1-mediated BRCA1 expression.

Authors:  Y Wang; O Deng; Z Feng; Z Du; X Xiong; J Lai; X Yang; M Xu; H Wang; D Taylor; C Yan; C Chen; A Difeo; Z Ma; J Zhang
Journal:  Oncogene       Date:  2015-08-03       Impact factor: 9.867

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.